SEC Form 4
Monopar Therapeutics Inc. (MNPR) insider trading
In the 12 months to Oct 26, 2026, 6 MNPR insiders reported open-market sales of $4.4M across 6 filings; one chief financial officer bought $104.9K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $4.4M
- 6 filings · 6 insiders
- Open-market purchases
- $104.9K
- 1 filing · Quan Anh Vu, Chief Financial Officer
- Pre-arranged sales (10b5-1)
- 5 of 6
- $4.0M of $4.4M sold (92%)
Who traded MNPR, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
MNPR daily close from Oct 27, 2025 to Oct 26, 2026, between $50.12 and $123.84, last $70.32. 6 sale and 1 purchase filings by 7 insiders, marked at their filing dates. Chandler Robinson, Chief Executive Officer: sold $2.6M across 1 filing, first filed Sep 28, 2026, last Sep 28, 2026. Christopher M. Starr, Director: sold $659.4K across 1 filing, first filed Oct 5, 2026, last Oct 5, 2026. Kim R. Tsuchimoto, Director: sold $455.6K across 1 filing, first filed Aug 28, 2026, last Aug 28, 2026. Raymond Anderson, Director: sold $351.8K across 1 filing, first filed Aug 28, 2026, last Aug 28, 2026. Arthur J. Klausner, Director: sold $343.9K across 1 filing, first filed Dec 19, 2025, last Dec 19, 2025. Quan Anh Vu, Chief Financial Officer: bought $104.9K across 1 filing, first filed Dec 29, 2025, last Dec 29, 2025. Patrice Rioux, Other: sold $111 across 1 filing, first filed Aug 27, 2026, last Aug 27, 2026.
Largest mark · tap a row for others
Chandler Robinson · Chief Executive Officer
Sale $2,556,851
29,056 shares at $88.00 avg
Filed Sep 28, 2026 · traded Sep 24
Pre-arranged (10b5-1) · close on filing date $83.72
Chandler Robinson · Chief Executive Officer
Chief Executive Officer
$2.6M soldChristopher M. Starr · Director
Director
$659.4K soldKim R. Tsuchimoto · Director
Director
$455.6K soldRaymond Anderson · Director
Director
$351.8K soldArthur J. Klausner · Director
Director
$343.9K soldQuan Anh Vu · Chief Financial Officer
Chief Financial Officer
$104.9K boughtPatrice Rioux · Other
Other
$111 soldOpen-market trades
7 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Chandler Robinson | Chief Executive Officer | $2.6M | — | 1 | 100% of sales | |
| Christopher M. Starr | Director | $659.4K | — | 1 | 100% of sales | |
| Kim R. Tsuchimoto | Director | $455.6K | — | 1 | 100% of sales | |
| Raymond Anderson | Director | $351.8K | — | 1 | 100% of sales | |
| Arthur J. Klausner | Director | $343.9K | — | 1 | — | |
| Quan Anh Vu | Chief Financial Officer | — | $104.9K | 1 | — | |
| Patrice Rioux | Other | $111 | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Christopher M. Starr Director | SalePre-arranged (10b5-1) | 8,400 | $78.50 | $659.4K | 5,173 | |
traded | Chandler Robinson Chief Executive Officer | SalePre-arranged (10b5-1) | 29,056 | $88.00 | $2.6M | 117,873 | |
traded | Raymond Anderson Director | SalePre-arranged (10b5-1) | 3,142 | $111.98 | $351.8K | 5,373 | |
traded | Kim R. Tsuchimoto Director | SalePre-arranged (10b5-1) | 4,090 | $111.39 | $455.6K | 3,605 | |
traded | Patrice Rioux Other | SalePre-arranged (10b5-1) | 1 | $111.26 | $111 | 5,065 | |
traded | Quan Anh Vu Chief Financial Officer | Purchase | 1,500 | $69.95 | $104.9K | 1,500 | |
traded | Arthur J. Klausner Director | Sale | 5,121 | $67.15 | $343.9K | 9,223 |
GET /stocks/filings/vX/form-4?tickers=MNPR&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"MNPR"
],
"issuer_cik": "0001645469",
"owner_cik": "0001235470",
"accession_number": "0001437749-26-032048",
"form_type": "4",
"filing_date": "2026-10-05",
"period_of_report": "2026-10-01",
"issuer_name": "Monopar Therapeutics",
"issuer_trading_symbol": "MNPR",
"owner_name": "STARR CHRISTOPHER M",
"is_director": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2970,
"transaction_price_per_share": 78.82,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 5972,
"transaction_value": 234095.4,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026."
},
{
"id": "F5",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4."
}
]
},
{
"tickers": [
"MNPR"
],
"issuer_cik": "0001645469",
"owner_cik": "0001235470",
"accession_number": "0001437749-26-032048",
"form_type": "4",
"filing_date": "2026-10-05",
"period_of_report": "2026-10-01",
"issuer_name": "Monopar Therapeutics",
"issuer_trading_symbol": "MNPR",
"owner_name": "STARR CHRISTOPHER M",
"is_director": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4631,
"transaction_price_per_share": 78.09,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 8942,
"transaction_value": 361634.79000000004,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026."
},
{
"id": "F4",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 32 records
- Option exercises18 records
- Tax withholding11 records
- Other3 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Monopar Therapeutics Inc.'s CEO sold stock?
Yes. Chandler Robinson (CEO) sold 29,056 shares ($2.6M) in Sep 2026, all under a pre-arranged 10b5-1 plan.
How current is MNPR’s insider data?
These are MNPR Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track MNPR insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for MNPR every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.